» Articles » PMID: 37426183

The Effects of Vitamin D on All-cause Mortality in Different Diseases: an Evidence-map and Umbrella Review of 116 Randomized Controlled Trials

Overview
Journal Front Nutr
Date 2023 Jul 10
PMID 37426183
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To conduct a solid evidence by synthesizing meta-analyses and updated RCTs about the effects of vitamin D on all-cause mortality in different health conditions.

Methods: Data sources: Pubmed, Embase, Web of Science, the Cochrane Library, Google Scholar from inception until 25th April, 2022. Study selection: English-language, meta-analyses and updated RCTs assessing the relationships between vitamin D and all-cause mortality. Data synthesis: Information of study characteristics, mortality, supplementation were extracted, estimating with fixed-effects model. A Measurement Tool to Assess Systematic Reviews, Grading of Recommendations Assessment, Development and Evaluation, and funnel plot was used to assess risk of bias. Main outcomes: All-cause mortality, cancer mortality, cardiovascular disease mortality.

Results: In total of 27 meta-analyses and 19 updated RCTs were selected, with a total of 116 RCTs and 149, 865 participants. Evidence confirms that vitamin D reduces respiratory cancer mortality (RR, 0.56 [95%CI, 0.33 to 0.96]). All-cause mortality is decreased in patients with COVID-19 (RR, 0.54[95%CI, 0.33 to 0.88]) and liver diseases (RR, 0.64 [95%CI, 0.50 to 0.81]), especially in liver cirrhosis (RR, 0.63 [95%CI, 0.50 to 0.81]). As for other health conditions, such as the general health, chronic kidney disease, critical illness, cardiovascular diseases, musculoskeletal diseases, sepsis, type 2 diabetes, no significant association was found between vitamin D and all-cause mortality.

Conclusions: Vitamin D may reduce respiratory cancer mortality in respiratory cancer patients and all-cause mortality in COVID-19 and liver disorders' patients. No benefits showed in all-cause mortality after vitamin D intervention among other health conditions. The hypothesis of reduced mortality with vitamin D still requires exploration.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=252921, identifier: CRD42021252921.

Citing Articles

Bioactive Compounds as Alternative Approaches for Preventing Urinary Tract Infections in the Era of Antibiotic Resistance.

Cipriani C, Carilli M, Rizzo M, Miele M, Sinibaldi-Vallebona P, Matteucci C Antibiotics (Basel). 2025; 14(2).

PMID: 40001388 PMC: 11851568. DOI: 10.3390/antibiotics14020144.


Vitamin D supplementation during intensive care unit stay is associated with improved outcomes in critically Ill patients with sepsis: a cohort study.

Li C, Zhao K, Ren Q, Chen L, Zhang Y, Wang G Front Cell Infect Microbiol. 2025; 14:1485554.

PMID: 39902186 PMC: 11788162. DOI: 10.3389/fcimb.2024.1485554.


Physical activity, Vitamin D, and all-cause/cardiovascular mortality: a prospective study in older Chinese adults.

Chen M, Cheng L, Yang S, Zhang Y BMC Geriatr. 2025; 25(1):38.

PMID: 39819506 PMC: 11740327. DOI: 10.1186/s12877-025-05687-1.


Vitamin D Supplementation in Critically Ill-Narrative Review.

Saric L, Domazet Bugarin J, Dosenovic S Nutrients. 2025; 17(1.

PMID: 39796590 PMC: 11723408. DOI: 10.3390/nu17010156.


Integrating Endocrine, Genomic, and Extra-Skeletal Benefits of Vitamin D into National and Regional Clinical Guidelines.

Wimalawansa S, Weiss S, Hollis B Nutrients. 2024; 16(22).

PMID: 39599755 PMC: 11597479. DOI: 10.3390/nu16223969.


References
1.
Putz-Bankuti C, Pilz S, Stojakovic T, Scharnagl H, Pieber T, Trauner M . Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int. 2012; 32(5):845-51. DOI: 10.1111/j.1478-3231.2011.02735.x. View

2.
Tian Y, Wang M, Zhao J . Crosstalk between Autophagy and Type I Interferon Responses in Innate Antiviral Immunity. Viruses. 2019; 11(2). PMC: 6409909. DOI: 10.3390/v11020132. View

3.
Keum N, Lee D, Greenwood D, Manson J, Giovannucci E . Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol. 2019; 30(5):733-743. PMC: 6821324. DOI: 10.1093/annonc/mdz059. View

4.
Coburn J, Maung H, Elangovan L, Germain M, Lindberg J, Sprague S . Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004; 43(5):877-90. DOI: 10.1053/j.ajkd.2004.01.012. View

5.
Wasse H, Huang R, Long Q, Zhao Y, Singapuri S, McKinnon W . Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: a randomized, double-blind, placebo-controlled pilot study. J Vasc Access. 2013; 15(2):88-94. PMC: 3979512. DOI: 10.5301/jva.5000187. View